Calcimedica Inc (CALC) Stock Price, Quote & News

Company Profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 952 5500

Website: calcimedica.com

Address:

505 Coast Boulevard South, Suite 307, La Jolla, United States

SilentWolverine Aug. 30 at 1:10 AM

NCRA top watch $10+ potential, super nova low float setup. MU and mega cap ties with AI power and memory theme $CALC $CCHH $VIVK $INHD …

0 · Reply

StocktwitsAragorn Aug. 29 at 8:38 PM

$CALC Of the 10 R/S's coming on Monday, this one seems to have real interest in it and it is not a Chinese scam. https://www.nasdaq.com/market-activity/stocks/calc/institutional-holdings

0 · Reply

Super_Marioo Aug. 29 at 1:05 PM

$CALC - 6 month chart indicates share price rarely dropped below 60c and long term chart indicates much a much higher average. recent pullback was probably the best bargain you will ever get. a reverse split is simply exchanging 1 dollar bill for 4 quarters.

3 · Reply

MUBSN Aug. 29 at 11:04 AM

$CALC AP waiting for financing (partnership or capital increase)

0 · Reply

Lyn30 Aug. 29 at 2:14 AM

$CALC I tried to buy but didn’t fill , I put at .40. Anyway I will try to buy Monday morning if it dips .

0 · Reply

Lyn30 Aug. 28 at 9:40 PM

$CALC Will buy for RS. Just looking cheap shares. One of the finest penny imo Analyst price target $9 with buy rating Post split OS will be 6.09M

0 · Reply

Adubstradesmini Aug. 28 at 9:18 PM

$ARTL $CALC $CHGA $FTFT $GCTK

0 · Reply

TwongStocks Aug. 28 at 8:10 PM

Tracking a total of 10 stocks with reverse splits on Monday. Nine on NASDAQ and one on the NYSE American. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am Monday morning. I'll have to split the summary into two parts. Part 1 of 2: $ARTL 1 for 9. Will reduce outstanding shares from approx 4.93m to approx 548k. $CALC 1 for 5. Will reduce outstanding shares from approx 34.5m to approx 6.9m. $CHGA 1 for 20. Will reduce outstanding shares from approx 21.1m to approx 1.05m. $FTFT 1 for 4. Will reduce outstanding shares from approx 32.31m to approx 8.08m. $GCTK 1 for 15. Will reduce outstanding shares from approx 11.97m to approx 798k.

0 · Reply

Super_Marioo Aug. 28 at 6:41 PM

$CALC - I am in at 0.45 have been successfully trading this ticker for almost a year. I knew the r/s would spook investors so did not bite in the pullback from a buck. I normally buy at 0.75 but not this time. can’t beat the bargain at this price. this is a good company with low risk of dilution and a good risk to value. good luck guys and who knows it could BOOM on Monday. good luck.

0 · Reply

Icemanja Aug. 28 at 4:40 PM

$CALC Time to start accumulating.

1 · Reply

Calcimedica Inc trading halted, news pending

2026-08-27T13:16:06.000Z - 3 days ago

CalciMedica to effect 1-for-5 reverse stock split

Aug 27, 2026, 9:00 AM EDT - 3 days ago

CalciMedica Announces One-for-Five Reverse Stock Split

2026-08-20T09:15:17.000Z - 10 days ago

CalciMedica initiated with a Buy at Guggenheim

Aug 11, 2026, 8:00 AM EDT - 19 days ago

CalciMedica Quarterly report: Q2 2026

2026-07-29T14:40:17.000Z - 4 weeks ago

CalciMedica announces FDA alignment on Phase 2b Auxora trial design

2026-07-29T14:35:38.000Z - 4 weeks ago

CalciMedica, FDA alignment de-risks regulatory path, says H.C. Wainwright

Jul 29, 2026, 7:00 AM EDT - 4 weeks ago

CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

2026-07-24T20:16:01.000Z - 5 weeks ago

CalciMedica files to sell 56.02M shares of common stock for holders

Jul 24, 2026, 8:00 AM EDT - 5 weeks ago

CalciMedica Registration statement: Registration filing

Jul 23, 2026, 8:00 AM EDT - 5 weeks ago

CalciMedica Proxy statement: Proxy filing

Jul 13, 2026, 8:00 AM EDT - 6 weeks ago

CalciMedica Proxy statement: Proxy filing

2026-06-24T11:11:04.000Z - 2 months ago

CalciMedica announces $49M private placement

2026-06-24T11:06:02.000Z - 2 months ago

CalciMedica announces FDA review of protocol amendment for Kourage trial

Jun 24, 2026, 7:01 AM EDT - 2 months ago

CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program

Jun 24, 2026, 7:00 AM EDT - 2 months ago

CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data

May 12, 2026, 8:00 AM EDT - 3 months ago

CalciMedica Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

Mar 3, 2026, 7:00 AM EST - 6 months ago

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

Mar 3, 2026, 7:00 AM EST - 6 months ago

CalciMedica Registration statement: Registration Filing

Jan 28, 2026, 7:00 AM EST - 7 months ago

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

Nov 13, 2025, 7:00 AM EST - 10 months ago

CalciMedica Registration statement: Registration Filing

Nov 12, 2025, 7:01 AM EST - 10 months ago

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Nov 12, 2025, 7:00 AM EST - 10 months ago

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Nov 10, 2025, 7:00 AM EST - 10 months ago

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Oct 14, 2025, 7:00 AM EDT - 11 months ago

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

Sep 2, 2025, 7:00 AM EDT - 1 year ago

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Jul 8, 2025, 7:00 AM EDT - 1 year ago

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 25, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

Jun 12, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

Jun 9, 2025, 8:00 AM EDT - 1 year ago

CalciMedica Proxy statement: Proxy Filing

May 14, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Apr 30, 2025, 8:00 AM EDT - 1 year ago

CalciMedica Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

CalciMedica Proxy statement: Proxy Filing

Apr 17, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Announces Presentations at Upcoming Medical Meetings

Apr 1, 2025, 7:00 AM EDT - 1 year ago

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

Mar 5, 2025, 7:00 AM EST - 1 year ago

CalciMedica Secures Credit Facility for Up to $32.5 Million

Mar 4, 2025, 7:00 AM EST - 1 year ago

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Feb 19, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 14, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

Nov 21, 2024, 8:00 AM EST - 1 year ago

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:00 AM EST - 1 year ago

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Nov 7, 2024, 7:00 AM EST - 1 year ago

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

Oct 30, 2024, 10:11 PM EDT - 1 year ago

CalciMedica Announces Pricing of Public Offering of Common Stock

Oct 30, 2024, 4:50 PM EDT - 1 year ago

CalciMedica Announces Proposed Public Offering of Common Stock

Oct 30, 2024, 7:00 AM EDT - 1 year ago

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 28, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Oct 16, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Sep 3, 2024, 8:00 AM EDT - 2 years ago

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 4:10 PM EDT - 2 years ago

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Jul 16, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Proxy statement: Proxy Filing

Jul 16, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Proxy statement: Proxy Filing

Jul 9, 2024, 7:30 AM EDT - 2 years ago

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Jul 8, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

Jul 1, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Set to Join Russell Microcap® Index

Jun 27, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 26, 2024, 4:05 PM EDT - 2 years ago

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

May 13, 2024, 4:05 PM EDT - 2 years ago

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

May 7, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

Apr 24, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Mar 28, 2024, 7:00 AM EDT - 2 years ago

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Mar 13, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 28, 2024, 6:57 PM EST - 2 years ago

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 13, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Feb 7, 2024, 4:05 PM EST - 2 years ago

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 31, 2024, 7:00 AM EST - 2 years ago

CalciMedica Registration statement: Registration Filing

Jan 22, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces Private Placement of up to Approximately $55 Million

Nov 9, 2023, 7:00 AM EST - 3 years ago

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

SilentWolverine Aug. 30 at 1:10 AM

NCRA top watch $10+ potential, super nova low float setup. MU and mega cap ties with AI power and memory theme $CALC $CCHH $VIVK $INHD …

0 · Reply

StocktwitsAragorn Aug. 29 at 8:38 PM

$CALC Of the 10 R/S's coming on Monday, this one seems to have real interest in it and it is not a Chinese scam. https://www.nasdaq.com/market-activity/stocks/calc/institutional-holdings

0 · Reply

Super_Marioo Aug. 29 at 1:05 PM

3 · Reply

MUBSN Aug. 29 at 11:04 AM

$CALC AP waiting for financing (partnership or capital increase)

0 · Reply

Lyn30 Aug. 29 at 2:14 AM

$CALC I tried to buy but didn’t fill , I put at .40. Anyway I will try to buy Monday morning if it dips .

0 · Reply

Lyn30 Aug. 28 at 9:40 PM

$CALC Will buy for RS. Just looking cheap shares. One of the finest penny imo Analyst price target $9 with buy rating Post split OS will be 6.09M

0 · Reply

Adubstradesmini Aug. 28 at 9:18 PM

$ARTL $CALC $CHGA $FTFT $GCTK

0 · Reply

TwongStocks Aug. 28 at 8:10 PM

0 · Reply

Super_Marioo Aug. 28 at 6:41 PM

0 · Reply

Icemanja Aug. 28 at 4:40 PM

$CALC Time to start accumulating.

1 · Reply

mrtmermer80 Aug. 28 at 4:36 PM

$CALC All you need to know that someone is collecting free shares pretty much:

0 · Reply

sh64 Aug. 28 at 4:00 PM

$CALC I will be piss off if this fall more after split cuz I added heavy

0 · Reply

mrtmermer80 Aug. 28 at 3:53 PM

$CALC Whoever is selling now eirher selling for big loss or they are short selling it. I never thought this will come back to 45cents again

1 · Reply

keokeostwiz Aug. 28 at 3:47 PM

$CALC CALC will have a remaining float of 1.65M and dropping as retail has hemorrhaged shares THU/FRI surely vacuumed by institutions which invested heavily just 2 months ago....these shares will not be sold any time soon.....simple math deduces no void will appear for selling...activist pressure will create buying momentum.....insiders and institutions have completed math models and hypotheses for potential returns....CALC will appreciate as the days move forward....the question remains can a sale be be mediated between management and activists......time will be the arbiter......JMO

1 · Reply

keokeostwiz Aug. 28 at 3:13 PM

$CALC Aug 31 will lower O/S count to 6.94M .... with an activist investor seeking to force actions to increase price... it does not take much to see the value of CALC to remaining shareholders...... as a minimum 200M bid is worth 28.57 per share........compared to AP therapy worth billions....owning any piece of CALC is a valuable possession.....JMO

1 · Reply

sh64 Aug. 28 at 2:54 PM

$CALC rock bottom added some more

0 · Reply

MUBSN Aug. 28 at 2:40 PM

$CALC 55k shares limited at 0.465 on the bid, and ..... pufff, were absorved in one hand.... or this changes right now or we will need another RS in two months

0 · Reply

mrtmermer80 Aug. 28 at 1:30 PM

$CALC I had to trim some of my holdings(I really didn’t want to) to buy more CALC yesterday. I couldn’t resisted to 46-49cents levels. Just my opinion, these levels are insanely cheap. Time will tell us what is all this about!

0 · Reply

pablo4 Aug. 27 at 8:41 PM

$CALC does anyone think that the institutions and insiders who just acquired last June the private placement at .8033/share are fixing to dump at half price 2 months later. Once the float on this one gets squeezed tight next week, we will see who holds the keys on this one. This is not a retailer controlled stock and with the float dropping to a minuscule number, where's the selling pressure going to come from. Those shorting now on R/S news are our firepower to come, IMO. Once split, I'll be the odd man out....I see a short squeeze coming sending us to 5 to 6.25, minimum. JMO

2 · Reply

Cap_00 Aug. 27 at 8:10 PM

$CALC self inflicted... RS does nothing... While RS is just a mechanism for increasing share price, it is a sell the event... So today, the share price that were already down some 50% from recent high, got another 20% hair cut while accomplishing absolutely nothing!

0 · Reply

sh64 Aug. 27 at 7:55 PM

$CALC bad day for share holders! We will overcome this

0 · Reply

mrtmermer80 Aug. 27 at 7:50 PM

$CALC all these funds that bought the offering lost pretty much half of their investment. I never though RS will sell off this much. It was priced in already. At least, they are implementing the RS very quick. We will have new shares count and share price on Monday.

0 · Reply

Market Cap	16.05M
Revenue (ttm)	0.00
Net Income (ttm)	-29.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	676,000
Avg Vol	1,608,304
Day's Range	N/A - N/A
Shares Out	34.14M
Stochastic %K	11%
Beta	0.91
Analysts	Strong Sell
Price Target	$10.00